Seelos Therapeutics, Inc.
SEELQ
$0.0005
$0.000.00%
OTC PK
| 06/30/2024 | 03/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -35.06% | -11.33% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -35.06% | -11.33% | |||
| Cost of Revenue | -78.58% | -88.30% | |||
| Gross Profit | 87.14% | 90.00% | |||
| SG&A Expenses | -18.01% | 13.22% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -47.02% | -23.43% | |||
| Operating Income | 48.16% | 24.42% | |||
| Income Before Tax | 164.19% | 51.15% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 164.19% | 51.15% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 164.19% | 51.15% | |||
| EBIT | 48.16% | 24.42% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 141.64% | 73.96% | |||
| Normalized Basic EPS | 120.85% | 89.14% | |||
| EPS Diluted | 107.54% | 73.96% | |||
| Normalized Diluted EPS | 120.77% | 89.14% | |||
| Average Basic Shares Outstanding | 54.15% | 87.45% | |||
| Average Diluted Shares Outstanding | 54.71% | 87.45% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||